Correlation Between Aptinyx and Histogen
Can any of the company-specific risk be diversified away by investing in both Aptinyx and Histogen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aptinyx and Histogen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aptinyx and Histogen, you can compare the effects of market volatilities on Aptinyx and Histogen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aptinyx with a short position of Histogen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aptinyx and Histogen.
Diversification Opportunities for Aptinyx and Histogen
Pay attention - limited upside
The 3 months correlation between Aptinyx and Histogen is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Aptinyx and Histogen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Histogen and Aptinyx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aptinyx are associated (or correlated) with Histogen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Histogen has no effect on the direction of Aptinyx i.e., Aptinyx and Histogen go up and down completely randomly.
Pair Corralation between Aptinyx and Histogen
If you would invest 2.60 in Histogen on December 29, 2024 and sell it today you would earn a total of 0.10 from holding Histogen or generate 3.85% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
Aptinyx vs. Histogen
Performance |
Timeline |
Aptinyx |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Histogen |
Risk-Adjusted Performance
Modest
Weak | Strong |
Aptinyx and Histogen Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Aptinyx and Histogen
The main advantage of trading using opposite Aptinyx and Histogen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aptinyx position performs unexpectedly, Histogen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Histogen will offset losses from the drop in Histogen's long position.Aptinyx vs. ABVC Biopharma | Aptinyx vs. CytomX Therapeutics | Aptinyx vs. Assembly Biosciences | Aptinyx vs. Instil Bio |
Histogen vs. Virax Biolabs Group | Histogen vs. Artelo Biosciences | Histogen vs. Curis Inc | Histogen vs. SAB Biotherapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Complementary Tools
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Fundamental Analysis View fundamental data based on most recent published financial statements |